CTMX
CytomX Therapeutics Inc
NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY
$3.88
-5.66% today
Updated 2026-06-05
Market cap
$653.11M
P/E ratio
—
P/S ratio
20.15x
EPS (TTM)
$-0.52
Dividend yield
—
52W range
$2 – $8
Volume
3.9M
CytomX Therapeutics Inc (CTMX) Insider transactions
Net insider activity
Net buying (7,588,403 shares)
Buy transactions
67
Sell transactions
33
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-17 | OGDEN, CHRISTOPHER | Chief Financial Officer | Sale | 19,323 | $6.42 | $124111.63 |
| 2026-03-17 | MCCARTHY, SEAN A. | Director, CEO | Sale | 118,969 | $6.42 | $764137.89 |
| 2026-03-17 | CHU, YU-WAYE | Chief Medical Officer | Sale | 21,279 | $6.42 | $136675.02 |
| 2026-03-17 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Sale | 31,492 | $6.42 | $202273.12 |
| 2026-02-02 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 325,000 | — | — |
| 2026-02-02 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 90,000 | — | — |
| 2026-02-02 | MCCARTHY, SEAN A. | Director, CEO | Buy | 980,000 | — | — |
| 2026-02-02 | MCCARTHY, SEAN A. | Director, CEO | Buy | 210,000 | — | — |
| 2026-02-02 | LESTER, RACHAEL | Chief Business Officer | Buy | 50,000 | — | — |
| 2026-02-02 | LESTER, RACHAEL | Chief Business Officer | Buy | 50,000 | — | — |
| 2026-02-02 | LESTER, RACHAEL | Chief Business Officer | Buy | 20,000 | — | — |
| 2026-02-02 | CHU, YU-WAYE | Chief Medical Officer | Buy | 300,000 | — | — |
| 2026-02-02 | CHU, YU-WAYE | Chief Medical Officer | Buy | 75,000 | — | — |
| 2026-02-02 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 250,000 | — | — |
| 2026-02-02 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 60,000 | — | — |
| 2025-11-06 | MCCARTHY, SEAN A. | Director, CEO | Sale | 101,793 | $4.54 | $461906.10 |
| 2025-10-20 | LESTER, RACHAEL | Chief Business Officer | Buy | 650,000 | — | — |
| 2025-09-26 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 78,250 | — | — |
| 2025-09-26 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 39,150 | — | — |
| 2025-09-26 | MCCARTHY, SEAN A. | Director, CEO | Buy | 570,000 | — | — |
| 2025-09-26 | MCCARTHY, SEAN A. | Director, CEO | Buy | 285,000 | — | — |
| 2025-09-26 | CHU, YU-WAYE | Chief Medical Officer | Buy | 87,500 | — | — |
| 2025-09-26 | CHU, YU-WAYE | Chief Medical Officer | Buy | 43,750 | — | — |
| 2025-09-26 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 36,300 | — | — |
| 2025-09-26 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 18,150 | — | — |
| 2025-06-16 | OGDEN, CHRISTOPHER | Chief Financial Officer | Sale | 10,614 | $2.69 | $28539.98 |
| 2025-06-16 | MCCARTHY, SEAN A. | Director, CEO | Sale | 55,511 | $2.69 | $149263.53 |
| 2025-06-16 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Sale | 13,884 | $2.69 | $37334.08 |
| 2025-06-13 | OGDEN, CHRISTOPHER | Chief Financial Officer | Sale | 37,500 | — | — |
| 2025-06-13 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 37,500 | — | — |
| 2025-06-13 | OGDEN, CHRISTOPHER | Chief Financial Officer | Sale | 1,641 | $2.95 | $4841.44 |
| 2025-06-13 | MCCARTHY, SEAN A. | Director, CEO | Sale | 150,000 | — | — |
| 2025-06-13 | MCCARTHY, SEAN A. | Director, CEO | Buy | 150,000 | — | — |
| 2025-06-13 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Sale | 37,500 | — | — |
| 2025-06-13 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 37,500 | — | — |
| 2025-06-11 | YOUNG, MATTHEW P. | Director | Buy | 38,000 | — | — |
| 2025-06-11 | SU, ZHEN | Director | Buy | 38,000 | — | — |
| 2025-06-11 | MOHINDRU, MANI | Director | Buy | 38,000 | — | — |
| 2025-06-11 | MEYERS, JAMES R | Director | Buy | 38,000 | — | — |
| 2025-06-11 | JONES, ELAINE V | Director | Buy | 38,000 | — | — |
| 2025-06-11 | GILBERT, HALLEY E | Director | Buy | 38,000 | — | — |
| 2025-06-11 | ASHWORTH, ALAN | Director | Buy | 38,000 | — | — |
| 2025-03-18 | ROWLAND, LLOYD A | General Counsel | Sale | 10,203 | $0.60 | $6111.60 |
| 2025-03-18 | OGDEN, CHRISTOPHER | Chief Financial Officer | Sale | 8,551 | $0.60 | $5122.05 |
| 2025-03-18 | MCCARTHY, SEAN A. | Director, CEO | Sale | 37,656 | $0.60 | $22555.94 |
| 2025-03-18 | CHU, YU-WAYE | Chief Medical Officer | Sale | 4,025 | $0.60 | $2410.97 |
| 2025-03-18 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Sale | 19,512 | $0.60 | $11687.69 |
| 2025-02-04 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 225,000 | — | — |
| 2025-02-04 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 115,000 | — | — |
| 2025-02-04 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 57,500 | — | — |
| 2025-02-04 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 44,000 | — | — |
| 2025-02-04 | MCCARTHY, SEAN A. | Director, CEO | Buy | 800,000 | — | — |
| 2025-02-04 | MCCARTHY, SEAN A. | Director, CEO | Buy | 390,000 | — | — |
| 2025-02-04 | MCCARTHY, SEAN A. | Director, CEO | Buy | 195,000 | — | — |
| 2025-02-04 | MCCARTHY, SEAN A. | Director, CEO | Buy | 180,000 | — | — |
| 2025-02-04 | CHU, YU-WAYE | Chief Medical Officer | Buy | 238,000 | — | — |
| 2025-02-04 | CHU, YU-WAYE | Chief Medical Officer | Buy | 115,000 | — | — |
| 2025-02-04 | CHU, YU-WAYE | Chief Medical Officer | Buy | 57,500 | — | — |
| 2025-02-04 | CHU, YU-WAYE | Chief Medical Officer | Buy | 56,000 | — | — |
| 2025-02-04 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 150,000 | — | — |
| 2025-02-04 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 140,000 | — | — |
| 2025-02-04 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 115,000 | — | — |
| 2025-02-04 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 57,500 | — | — |
| 2025-02-04 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 35,000 | — | — |
| 2025-02-04 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 30,000 | — | — |
| 2024-08-20 | ROWLAND, LLOYD A | General Counsel | Sale | 11,250 | — | — |
| 2024-08-20 | ROWLAND, LLOYD A | General Counsel | Buy | 11,250 | — | — |
| 2024-08-20 | ROWLAND, LLOYD A | General Counsel | Sale | 4,181 | $1.23 | $5138.87 |
| 2024-08-20 | OGDEN, CHRISTOPHER | Chief Financial Officer | Sale | 6,875 | — | — |
| 2024-08-20 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 6,875 | — | — |
| 2024-08-20 | OGDEN, CHRISTOPHER | Chief Financial Officer | Sale | 1,984 | $1.23 | $2438.53 |
| 2024-08-20 | MCCARTHY, SEAN A. | Director, CEO | Sale | 37,500 | — | — |
| 2024-08-20 | MCCARTHY, SEAN A. | Director, CEO | Buy | 37,500 | — | — |
| 2024-08-20 | MCCARTHY, SEAN A. | Director, CEO | Sale | 13,898 | $1.23 | $17082.03 |
| 2024-08-20 | LANDAU, JEFFREY B | Chief Business Officer | Sale | 11,250 | — | — |
| 2024-08-20 | LANDAU, JEFFREY B | Chief Business Officer | Buy | 11,250 | — | — |
| 2024-08-20 | LANDAU, JEFFREY B | Chief Business Officer | Sale | 4,181 | $1.23 | $5138.87 |
| 2024-08-20 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Sale | 11,250 | — | — |
| 2024-08-20 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Buy | 11,250 | — | — |
| 2024-08-20 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Sale | 4,181 | $1.23 | $5138.87 |
| 2024-06-12 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 75,000 | — | — |
| 2024-06-12 | OGDEN, CHRISTOPHER | Chief Financial Officer | Buy | 17,500 | — | — |
| 2024-05-15 | YOUNG, MATTHEW P. | Director | Buy | 38,000 | — | — |
| 2024-05-15 | SU, ZHEN | Director | Buy | 38,000 | — | — |
| 2024-05-15 | MOHINDRU, MANI | Director | Buy | 38,000 | — | — |
| 2024-05-15 | MEYERS, JAMES R | Director | Buy | 38,000 | — | — |
| 2024-05-15 | JONES, ELAINE V | Director | Buy | 38,000 | — | — |
| 2024-05-15 | GILBERT, HALLEY E | Director | Buy | 38,000 | — | — |
| 2024-05-15 | ASHWORTH, ALAN | Director | Buy | 38,000 | — | — |
| 2024-03-26 | MCCARTHY, SEAN A. | Director, CEO | Sale | 109,768 | — | — |
| 2024-03-26 | MCCARTHY, SEAN A. | Director, CEO | Buy | 109,768 | $1.57 | $172873.62 |
| 2024-03-20 | SU, ZHEN | Director | Buy | 76,000 | — | — |
| 2024-03-19 | ROWLAND, LLOYD A | General Counsel | Sale | 5,268 | $2.09 | $10986.41 |
| 2024-03-19 | OGDEN, CHRISTOPHER | SVP, Finance and Accounting | Sale | 2,971 | $2.09 | $6196.02 |
| 2024-03-19 | MCCARTHY, SEAN A. | Director, CEO | Sale | 20,223 | $2.09 | $42175.07 |
| 2024-03-19 | LANDAU, JEFFREY B | Chief Business Officer | Sale | 6,562 | $2.09 | $13685.05 |
| 2024-03-19 | BELVIN, MARCIA | SVP, Chief Scientific Officer | Sale | 12,795 | $2.09 | $26683.97 |
| 2024-01-18 | ROWLAND, LLOYD A | General Counsel | Buy | 100,000 | — | — |
| 2024-01-18 | ROWLAND, LLOYD A | General Counsel | Buy | 75,000 | — | — |
| 2024-01-18 | ROWLAND, LLOYD A | General Counsel | Buy | 25,000 | — | — |
Frequently asked questions
Are CTMX insiders buying or selling?
Over the transactions on record, CTMX insiders have been net buyers, with about $2.09M in stock sold across 33 sales, against 1 open-market purchase.
Does insider selling at CTMX mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which CTMX insiders are selling the most?
Recent selling is concentrated in a few names. MCCARTHY, SEAN A. accounts for the largest share on record, with about $1.46M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.